885 related articles for article (PubMed ID: 18804418)
1. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.
Linardou H; Dahabreh IJ; Kanaloupiti D; Siannis F; Bafaloukos D; Kosmidis P; Papadimitriou CA; Murray S
Lancet Oncol; 2008 Oct; 9(10):962-72. PubMed ID: 18804418
[TBL] [Abstract][Full Text] [Related]
2. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer.
Dahabreh IJ; Linardou H; Siannis F; Kosmidis P; Bafaloukos D; Murray S
Clin Cancer Res; 2010 Jan; 16(1):291-303. PubMed ID: 20028749
[TBL] [Abstract][Full Text] [Related]
3. KRAS mutation: should we test for it, and does it matter?
Roberts PJ; Stinchcombe TE
J Clin Oncol; 2013 Mar; 31(8):1112-21. PubMed ID: 23401440
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors.
Kim WY; Prudkin L; Feng L; Kim ES; Hennessy B; Lee JS; Lee JJ; Glisson B; Lippman SM; Wistuba II; Hong WK; Lee HY
Cancer; 2012 Aug; 118(16):3993-4003. PubMed ID: 22359227
[TBL] [Abstract][Full Text] [Related]
5. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
7. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
8. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.
Mao C; Qiu LX; Liao RY; Du FB; Ding H; Yang WC; Li J; Chen Q
Lung Cancer; 2010 Sep; 69(3):272-8. PubMed ID: 20022659
[TBL] [Abstract][Full Text] [Related]
9. De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer.
Takeda M; Okamoto I; Fujita Y; Arao T; Ito H; Fukuoka M; Nishio K; Nakagawa K
J Thorac Oncol; 2010 Mar; 5(3):399-400. PubMed ID: 20186026
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer.
Califano R; Landi L; Cappuzzo F
Drugs; 2012 Jun; 72 Suppl 1():28-36. PubMed ID: 22712795
[TBL] [Abstract][Full Text] [Related]
11. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer.
Kawahara A; Taira T; Azuma K; Tominaga M; Hattori S; Kawahara M; Abe H; Yamaguchi T; Akiba J; Takamori S; Hayashi A; Kage M
Lung Cancer; 2012 Oct; 78(1):39-44. PubMed ID: 22858448
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
13. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
14. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
[TBL] [Abstract][Full Text] [Related]
15. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.
Ludovini V; Bianconi F; Pistola L; Pistola V; Chiari R; Colella R; Bellezza G; Tofanetti FR; Siggillino A; Baldelli E; Flacco A; Giuffrida D; Sidoni A; Crinò L
Cancer Chemother Pharmacol; 2012 May; 69(5):1289-99. PubMed ID: 22302407
[TBL] [Abstract][Full Text] [Related]
16. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP
BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
18. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
[TBL] [Abstract][Full Text] [Related]
19. [Resistances to targeted therapies and strategy for following therapeutic lines in metastatic NSCLC].
Brosseau S; Oulkhouir Y; Naltet C; Zalcman G
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S27-33. PubMed ID: 26118873
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]